Boston, MA—Family- and patient-related factors were identified as the most significant barriers to early end-of-life discussions, as well as to the timely discontinuation of cancer-directed therapies in the palliative setting, according to the results of a multicenter survey of oncologists in Ontario, Canada.
San Antonio, TX—A genomic classifier is now available that can predict a low or high risk for metastasis in men with prostate cancer who have rising prostate-specific antigen (PSA) after a prostatectomy. The good news is that this test is reimbursable by Medicare.
Washington, DC—The COME HOME initiative, a 7-member oncology medical home practice partnership, has documented significant reductions in hospitalization rates, inpatient days, and total cost of care of approximately $5 million over a 6-month period, said Barbara L. McAneny, MD, at the Fifth Annual Conference of the Association for Value-Based Cancer Care.
- Darzalex First Monoclonal Antibody Approved by the FDA for Multiple Myeloma
- Ninlaro First Oral Proteasome Inhibitor Approved for Multiple Myeloma
- Empliciti Second Monoclonal Antibody Approved by the FDA for Multiple Myeloma
- Cotellic Approved for Patients with Advanced Melanoma
- Portrazza Receives FDA Approval for Metastatic Squamous NSCLC
- FDA Approved Tagrisso for Patients with NSCLC and EGFR Mutation, Together with a Companion Diagnostic Test
Boston, MA—A new guidance statement from the American Society of Clinical Oncology (ASCO) and the American Academy of Hospice and Palliative Medicine (AAHPM) provides the first formal, consensus-based recommendations regarding high-quality primary palliative care in oncology, according to Kathleen E. Bickel, MD, MPhil, Assistant Professor of Medicine, Geisel School of Medicine at Dartmouth, Hanover, NH.
Boston, MA—Delivering the keynote lecture at the 2015 Palliative Care in Oncology Symposium, Howard L. McLeod, PharmD, Medical Director of the DeBartolo Family Personalized Medicine Institute at Moffitt Cancer Center, Tampa, FL, discussed advances in personalized medicine as they relate to palliative care, as well as the continuing challenges in cancer care.
At the Fifth Annual Conference of the Association for Value-Based Cancer Care in Washington, DC, Grant Lawless, RPh, MD, FACP, of the University of Southern California, Los Angeles, moderated a multidisciplinary panel on value-based care for patients with multiple myeloma.
Page 1 of 2
Results 1 - 10 of 18
Results 1 - 10 of 18